Investigating levodopa-induced dyskinesias in the parkinsonian primate
- PMID: 10762135
Investigating levodopa-induced dyskinesias in the parkinsonian primate
Abstract
Research into the cause of dyskinesias arising from levodopa treatment has been vexingly limited, partly due to the lack of an inexpensive and widely available animal model. Rodents do not develop levodopa-induced dyskinesias in a clinically recognizable form. However, nonhuman primates with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism readily develop levodopa-induced dyskinesias that are virtually indistinguishable from those seen in patients with Parkinson's disease. We have developed and validated a five-point Global Primate Dyskinesia Rating Scale to accurately measure these dyskinesias. Monkeys with MPTP-induced parkinsonism were then investigated to evaluate the relationship between dyskinesias, parkinsonism and severity of the nigrostriatal lesion. All parkinsonian animals were responsive to levodopa, and developed dyskinesias within 2-3 days of levodopa administration. Monkeys treated with only a single injection of MPTP also developed dyskinesias, even though they were not parkinsonian. It would appear that there is a different threshold of striatal dopamine depletion for parkinsonism and dyskinesias in the monkey. Finally, three hypotheses, put forward to explain the genesis of dyskinesias, are reviewed, and various experimental approaches suggested for each.
Similar articles
-
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.Mov Disord. 2000 May;15(3):459-66. doi: 10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3. Mov Disord. 2000. PMID: 10830409
-
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).Mov Disord. 1995 Nov;10(6):731-40. doi: 10.1002/mds.870100606. Mov Disord. 1995. PMID: 8749992
-
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.Mov Disord. 1998 Sep;13(5):798-802. doi: 10.1002/mds.870130507. Mov Disord. 1998. PMID: 9756148
-
Molecular basis of levodopa-induced dyskinesias.Ann Neurol. 2000 Apr;47(4 Suppl 1):S70-8. Ann Neurol. 2000. PMID: 10762134 Review.
-
The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.Ann Neurol. 2000 Apr;47(4 Suppl 1):S105-12; discussion S112-4. Ann Neurol. 2000. PMID: 10762137 Review.
Cited by
-
Surgical insights into Parkinson's disease.J R Soc Med. 2006 May;99(5):238-44. doi: 10.1177/014107680609900515. J R Soc Med. 2006. PMID: 16672757 Free PMC article. Review.
-
Non-human primate models of PD to test novel therapies.J Neural Transm (Vienna). 2018 Mar;125(3):291-324. doi: 10.1007/s00702-017-1722-y. Epub 2017 Apr 8. J Neural Transm (Vienna). 2018. PMID: 28391443 Review.
-
Cell-based therapies for Parkinson's disease: past, present, and future.Antioxid Redox Signal. 2009 Sep;11(9):2189-208. doi: 10.1089/ars.2009.2654. Antioxid Redox Signal. 2009. PMID: 19485712 Free PMC article. Review.
-
Modeling Parkinson's disease in primates: The MPTP model.Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009308. doi: 10.1101/cshperspect.a009308. Cold Spring Harb Perspect Med. 2012. PMID: 22393538 Free PMC article.
-
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.J Neurosci. 2001 Aug 1;21(15):5494-500. doi: 10.1523/JNEUROSCI.21-15-05494.2001. J Neurosci. 2001. PMID: 11466420 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
